ResMed launches CPAP sleep apnoea therapy platform in Europe
9 March 2010
ResMed (NYSE:RMD) has introduced its new S9 Series sleep
apnoea therapy platform in Europe.
The S9 Series combines a sleek design with superior functionality
and more comfort. Combined climate control and humidification
delivers unsurpassed comfort to the patient by controlling both the
temperature and humidity that the patient breathes.
The S9 Series is expected to help more sleep apnoea patients
adhere to the treatment, but also help sleep professionals make more
informed decisions.
The most effective treatment for sleep apnoea is Continuous
Positive Airway Pressure (CPAP) therapy. In this non-invasive
treatment, air is pressurised by a small device and delivered to the
airway of the patient through a mask that fits on/over the nose, or
nose and mouth. The pressurised air keeps the upper airway open and
helps the person experience a restful night’s sleep without
interruptions caused by apnoeas.
Michael Farrell, SVP of the Global Sleep Business Unit at ResMed
said, “ResMed is convinced that the S9 Series will contribute to
improved patient comfort, compliance and outcomes and in the long
run, should lead to more healthcare savings. Air is delivered
quietly and comfortably at the precise temperature and humidity that
the sleeping patient, provider, and physician have set, making a
significant difference in patient comfort. In addition to the
advanced features, clinical algorithms and connectivity options, the
S9 Series design fits right into any patient’s home. This next
generation CPAP and APAP series no longer has the look and feel of
hospital equipment.”
Sleep apnoea is one of the more common, and yet highly
undiagnosed, sleep disorders. The condition causes the sufferer to
stop breathing throughout the night. There are three types of sleep
apnoea; obstructive, mixed and central. Obstructive sleep apnoea
(OSA) is the most common and is marked by the collapse or
obstruction of the airway during sleep. The new S9 system treats OSA
while also detecting central sleep apnoea and reporting a central
apnea index for follow-up by providers and physicians.
A new study published in Science Translational Medicine,
shows that it is very hard to catch up on lost sleep, and that the
fatigue that follows interrupted sleep presents safety risks in
traffic and at the workplace. A person with untreated sleep apnoea
does not have the opportunity to catch up on lost sleep since the
condition is a daily occurrence.
In addition to road and workplace accidents, the condition is
responsible for contributing to extreme sleepiness, nodding off
during the day, inability to perform optionally at work, elevated
levels of blood pressure, heart disease, diabetes, episodes of
stroke, and depression. While many people perceive snoring as a
common harmless problem, it can be a clear sign of this serious
condition.